Spinal Radiosurgery: a Neurosurgical Perspective
Overview
Authors
Affiliations
Spine stereotactic radiosurgery (SSRS) is proving to be one of the most significant advances in the treatment of both metastatic and primary spine tumors. High-dose hypofractionated and single fraction radiation appear to convey better local tumor control than conventional radiation for tumors considered radioresistant, such as renal cell carcinoma and melanoma. Multiple series have demonstrated control rates greater than 85% which appears to be histology independent. The markedly improved local control rates compared to conventional radiation techniques are beginning to change the treatment paradigms for spine tumors. Recent evidence in the literature reflects the integration of SSRS in the treatment of metastatic and primary malignant and benign spine tumors as the principle treatment or as a neoadjuvant or postoperative adjuvant therapy. For instance, as confidence grows with the use of SSRS as a postoperative adjuvant, surgical resection of metastatic disease has become less aggressive with the expectation that radiation can control residual disease. Despite high dose radiation delivery within millimeters of the spinal cord, toxicity has been limited with rare cases of radiation-induced myelopathy. The establishment of spinal cord and other critical structure tolerances is essential to the continued evolution of SSRS, as radiation oncologists begin to use this modality to treat spinal cord compression. This paper reviews the neurosurgical integration of SRS into spine practice.
The role of spine stereotactic radiosurgery for patients with breast cancer metastases.
Taori S, Adida S, Tang A, Rajan A, Sefcik R, Burton S J Neurooncol. 2024; 167(2):257-266.
PMID: 38355870 DOI: 10.1007/s11060-024-04599-1.
Akanda Z, McKay M Ann Transl Med. 2023; 11(11):386.
PMID: 37970608 PMC: 10632584. DOI: 10.21037/atm-22-3076.
Gerszten P, Quader M, Novotny Jr J, Flickinger J J Radiosurg SBRT. 2018; 1(3):197-202.
PMID: 29296317 PMC: 5725316.